The company is based on values that are very dear to us, namely highly attentive customer care, quality products, as well as innovation, and on its collaboration with many key opinion leaders in the dentistry field.
Both a pioneer and a leader, Panthera Dental has successfully combined creativity, science and know-how to develop its proprietary innovative technology and is now able to offer next-generation products to the dental industry worldwide.
Gabriel Robichaud leads the strategic direction and the overall development of the company. He graduated from Laval University in Business Administration and from Cégep de Lévis-Lauzon in Industrial Robotics. He then followed additional training programs in management, including one in Project Management at École de technologie supérieure (ÉTS). Gabriel is a senior executive with more than 15 years of experience in operations management for medtech companies with an emphasis on personalized medicine. He has been instrumental in the launch of several start-up companies that reached sustainable growth and great success. These success stories have been achieved through his fresh vision, leadership, and strong sense of innovation. Gabriel draws on a creative and strategic approach to solve issues and manage effectively. Since the beginning of his career, he has often played a leading role in product development and recruitment to build high-performing teams.
Béatrice Robichaud is responsible for new product launches, product introduction at the international level, and customer technical support. She is the co-founder of Panthera Dental, a lecturer, and a Specialist in High Technology CAD/CAM Dental Products. She graduated in Telecommunications at Collège radio télévision de Québec (CRTQ). During her career, she led several lectures in English and French in 10 different countries and trained over 400 dental specialists in the CAD/CAM dental field.
Kyle Steadman is a seasoned manager with over 15 years of experience in financial management, controlling, planning and corporate development activities. He is responsible for Panthera Dental’s overall financial management, including the company’s financial reporting, long-range business planning, treasury and internal controls and he is an active participant in corporate development. Kyle has gained growing experience in international corporate activities working in both public and private Med-Tech companies on various projects including computer system migrations, internal control system set-up and surveillance, international taxation and change management..
David “Kim” Solomon is responsible for sales, marketing, and brand development for Panthera Dental in the United States. He is a sales and marketing executive with expertise in business development, product launch, CAD/CAM digital technology, and clinical/restorative solutions. He is specialized in both direct and distributor sales channels with focus on B2B and B2C. Through the years, Kim has built sales and marketing teams for public and private dental companies in the clinical/restorative, medical device, and laboratory service industries.
Pierre Cantin has more than 25 years of experience in business development, business networking and new market development. He has held senior management roles and acted as vice-president in well-known companies such as KPMG and Caisse de dépôt et placement du Québec. He has also conducted international trade missions for the Société générale de financement du Québec and worked closely on projects to attract foreign companies on behalf of Investissement Québec.
A graduate of the École de Management of Normandie, France, Marc has over fifteen years of experience in international business development , in establishing alliances and partnerships, and in project management in the healthcare industry . He has previously managed the international deployment of small and medium sized Canadian, American and French enterprises, through the opening of new markets, various new product launches and the implementation of sales and marketing team management.
Jean-Pierre Desmarais is the CEO of Innovitech Inc., an innovation expert firm in the field of Medical Technologies and Aerospatiale. Jean-Pierre has more than 40 years’ experience in the medical device industry from large multinational to small startups and a vast expertise in Medical Technology from inception to commercialization; from early R&D, pre-clinical and clinical research, commercial approval globally; inclusive of USFDA, EU CE Australia, Japan; global reimbursement programs and early strategic commercialization globally. He served as President of Piramal Healthcare Bio-Orthopedics, a spin off from Montréal engineering school École Polytechnique, in the field of cartilage repair, that resulted into the technology acquisition in 2016 by Smith+Nephew, an orthopedic giant company. Prior to Piramal, Jean-Pierre worked at CryoCath Technologies as the Chief Scientific Officer in the field of cardiac electrophysiology. This Canadian technology startup from Montréal, founded in 1995 and acquired in 2008 by Medtronic USA for 400M$., treated more than 350,000 individuals around the world and had a profound healthcare and quality of life impact in the lives of people suffering from of Atrial Fibrillation.
Gabriel Robichaud is a senior executive with more than 15 years of experience in operations management for medtech companies with an emphasis on personalized medicine. He has been instrumental in the launch of several start-up companies that reached sustainable growth and great success. These success stories have been achieved through his fresh vision, leadership, and strong sense of innovation. Gabriel draws on a creative and strategic approach to solve issues and manage effectively. Since the beginning of his career, he has often played a leading role in product development and recruitment to build high-performing teams.
Diane Robichaud is Laboratory Director at Panthera Dental and a member of the research and development team working on mandibular advancement devices for the treatment of snoring and obstructive sleep apnea. Having worked in the field of dentistry for more than 30 years, Diane is a member of the Ordre des techniciens et techniciennes dentaires du Québec and holds a laboratory management permit. She received two awards for the excellence of her work and co-founded a dental laboratory that she subsequently sold to dedicate herself to sleep problems at Panthera. Holder of a certificate in accounting sciences from Laval University, the daily management, administration and development of a SME brought her experience in different administration and management activity sectors. She is passionate about healthy sleep.
Dr. Marengère is a Managing Partner with TVM Capital Life Sciences. Luc has overseen the implementation of the Canadian operations and the North American investment strategy. Also, Luc co-manages the relationship with strategic partner Eli Lilly. Dr. Marengère has joined TVM LSV VII in 2011 and has more than 20 years of venture capital experience. Luc oversaw a number of investments on behalf of TVM LSV VII and is a Director on the Boards of Ixchelsis Ltd (UK); PRCL Pharma (Canada); Aurka Pharma (Canada); Panthera Dental Inc. (Canada); FAAH Pharma (Canada); Kaneq Biosciences (Canada), Acer Therapeutics (USA); TeserX Pharma (USA). Luc was a Director on the Board of Colucid Pharma (USA) sold to Eli Lilly in March 2017 for US$960M. Prior to joining TVM Capital, Luc was a Managing General Partner with VG Partners where he founded and ran the VG Advanced Life Sciences Fund (VG ALSF – CDN$230M). Luc was a Director on the Boards of Trillium Technologies Inc. (NASDAQ listed); Cytochroma Inc., (Sold to Opko for US$400M); Aegera Therapeutics Inc. (Sold to Pharmascience Ltd); Cita Neuropharma (sold to Vernalis Plc for US$85M) and lastly Argos Therapeutics Inc., (NASDAQ listed). Luc also invested in VisualSonics Inc. (sold to Sonosite for US$75M).
Crédit Mutuel Equity is the Private Equity branch of Crédit Mutuel Alliance Fédérale. For 40 years, we have supported business leaders by providing equity at all stages of their companies’ development, from seed phase to buyout. We uphold a responsible, sustainable, and human vision of our role as investor through a close relationship and presence that benefits to each other interest. Crédit Mutuel Equity has deep regional roots in France as well as a strong presence in North America (Canada, USA) and Europe (Germany, Switzerland), allowing companies to tap into new sources of growth.
9105 rue John-Simons
Quebec, QC Canada,
+ 1 (418) 527-0388
22343 La Palma Ave, Ste 128
Yorba Linda, CA
+ 1 (418) 527-0388
38 rue Jean Mermoz
+ 1 (418) 527-0388